Need for combined therapy for a rare case of autoimmune autonomic ganglionopathy: A case report

Table 1 Autoantibody control for myasthenia gravis

Exam	Method	Result	Result classification
			Negative	Grey-zone	Positive
Anti-AChR	RIA	< 0.1 nmol/L	≤ 0.1	0.2-0.5	≥ 0.6
Anti-MuSK	RIA	< 0.015 nmol/L	< 0.015 nmol/L	0.015-0.03	> 0.03
Anti-LRP4	IFA (cell based assay)		< 10	10	> 10

Anti-AChR: Acetyl-Choline receptor ganglionic neuronal auto-antibodies; Anti-MuSK: Muscle-specific tyrosine kinase auto-antibodies; Anti-LRP4: Low-density lipoprotein receptor-related protein autoantibodies; RIA: Radioimmunoprecipitation assay, IFA: Indirect immunofluorescence assay.

Table 2 Antineuronal antibodies control

Exam	Method	Result	Result classification
			Negative	Grey-zone	Positive
NMDA-R	IFA (cell based assay)	< 10	< 10	10	> 10
AMPA-R1		< 10
GABAB-R		< 10
LGI1		< 10
DPPX		< 10
CASPR2		< 10	< 10	10	≥ 100

NMDA-R: N-Methyl D-aspartate Receptor; AMPA-R1: A-amino-3-hydroxy-5-Methyl-4-isoxazolepropionic acid Receptor; GABAB-R: Gamma-amino butyric acid B Receptor; LGI1: Leukin-rich glioma inactivated; DPPX: Dipeptidyl-peptidase-like protein 6; CASPR2: Contactin-associated protein-like 2.